

GP1644

PATENT
Attorney Docket No. HAR-001DV
(6615/3)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

17/IDS

APPLICANTS: Strominger et al.
SERIAL NO.: 08/991,628 GROUP NO.: 1644
FILING DATE: November 5, 1997 EXAMINER: T. Cunningham
TITLE: IDENTIFICATION OF SELF AND NON-SELF ANTIGENS IMPLICATED
IN AUTOIMMUNE DISEASE

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any documents referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231, on this 10th day of February, 2000.

February 10, 2000
Date of Signature

Brenda T. Kowalczyk
Brenda T. Kowalczyk

Assistant Commissioner for Patents
Washington, D.C. 20231

FEB 17 2000


Sir:

TECH CENTER 1600/2900

Submitted herewith are:

Transmittal Form (1 pg.); Supplemental Information Disclosure Statement (2 pgs.); Supplemental PTO-1449 (1 pg.); Cited art C8; and a mailroom postcard and this Certificate of First Class Mailing.

BRESNAHA6615/3.941547-1



TRANSMITTAL FORM

Application Serial No.:	08/991,628
Filing Date:	November 5, 1997
First Named Inventor	Strominger et al.
Group Art Unit	1644
Examiner Name	T. Cunningham
Attorney Docket No.	HAR-001DV (6615/3)

ENCLOSURES (check all that apply)

- | | | |
|--|---|---|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Check Attached
<input type="checkbox"/> Copy of Fee Transmittal Form
<input type="checkbox"/> Amendment/Response
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____]
<input type="checkbox"/> Extension of Time Request
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement
<input checked="" type="checkbox"/> Supplemental Form PTO-1449
<input checked="" type="checkbox"/> Copies of IDS Citations
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application | <input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553)
<input type="checkbox"/> Formal Drawing(s)
<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney (Revocation of Prior Powers)
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application
<input type="checkbox"/> Small Entity Statement
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> After Allowance Communication to Group | <input type="checkbox"/> Appeal Communication to Board of Patent Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Return Receipt Postcard
<input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8
<input type="checkbox"/> Additional Enclosure(s) (please identify below)

FEB 17 2000
TECH CENTER 1600/2300 |
|--|---|---|

CORRESPONDENCE ADDRESS


Direct all correspondence to: Patent Administrator
Testa, Hurwitz & Thibault, LLP
High Street Tower
125 High Street
Boston, MA 02110
Tel. No.: (617) 248-7000
Fax No.: (617) 248-7100

SIGNATURE BLOCK

Respectfully submitted,

Date: February 10, 2000
Reg. No. 44,559
Tel. No.: (617) 248-7103
Fax No.: (617) 248-7100

Maureen A. Bresnahan
Maureen A. Bresnahan
Attorney for Applicants
Testa, Hurwitz & Thibault, LLP
High Street Tower
125 High Street
Boston, MA 02110



PATENT
Attorney Docket No. HAR-001DV
(6615/3)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Strominger et al.
SERIAL NO.: 08/991,628 GROUP NO.: 1644
FILING DATE: November 5, 1997 EXAMINER: T. Cunningham
TITLE: IDENTIFICATION OF SELF AND NON-SELF ANTIGENS IMPLICATED
IN AUTOIMMUNE DISEASE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the provisions of 37 C.F.R. § 1.97, Applicants hereby make of record the references listed on the accompanying PTO Form 1449 for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the references are enclosed.

REMARKS


In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed (CHECK ONE):

- ☐ (1) within three (3) months of the **Filing Date** or before the mailing date of the **First Office Action** on the merits; or
- ☒ (2) after the period defined in (1) but before the mailing date of a **Final Rejection** or **Notice of Allowance**, and
- ☒ the requisite Statement is below, **OR**
- ☐ the requisite fee under Rule 1.17(p), namely **\$240.00**, is included herein, or
- ☐ (3) after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, **AND**
- ☐ Applicant hereby Petitions the Commissioner to accept and consider the attached Information Disclosure Statement, **AND**
- ☐ the requisite Statement is below, **AND**

Information Disclosure Statement

Serial No.: 08/991,628

Page 2 of 2



- ☐ the requisite petition fee due under Rule 1.17(i)(I), namely \$130.00 is included herein.

It is respectfully requested that each of the references shown on the attached Form PTO-1449 be made of record in this application.

STATEMENT

As required under §1.97(e), Applicants, through the undersigned, hereby state either that [check the appropriate space]:

- ☒ 1. [E]ach item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application **not more than** three months prior to the filing date of the Information Disclosure Statement; or
- ☐ 2. [N]o item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any** individual designated in §1.56(c) **more than** three months prior to the filing of the Information Disclosure Statement.

FEE AUTHORIZATION


Should any fee associated with the submission of this paper not be attached hereto as a check, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 20-0531. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,

Date: February 10, 2000
Reg. No. 44,559

Maureen A. Bresnahan
Maureen A. Bresnahan
Attorney for Applicants
Testa, Hurwitz, & Thibault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

Tel. No.: (617) 248-7103
Fax No.: (617) 248-7100



FORM PTO - 1449

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT

ATTORNEY DOCKET NO.: HAR-001DV

APPLICANTS: Strominger et al.

SERIAL NO.: 08/991,628

FILING DATE: November 5, 1997

GROUP: 1644

U.S. PATENT DOCUMENTS

EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAM. INIT.	DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Place of Publication, Relevant Pages, Date)							
2/25/00	C8	Hogenkamp et al., "Nucleotide Sequence of the Right 10% of Adenovirus Type 12 DNA Encoding the Entire Region E4", <i>Nucleic Acids Research</i> , Vol. 18, No. 10, April 1990, p. 3065.						
EXAMINER <i>M. D. [Signature]</i>				DATE CONSIDERED 2/25/00				

BRESNAHA6615/3.941522-1